A neurocognitive model for understanding treatment action in
... memory task may be attributed to decreased retrieval effort for positive words. It should be noted here that doubts have been raised about the antidepressant efficacy of reboxetine in recent meta-analyses [48]. However, it has been shown that these meta-analyses have produced biased accounts of the ...
... memory task may be attributed to decreased retrieval effort for positive words. It should be noted here that doubts have been raised about the antidepressant efficacy of reboxetine in recent meta-analyses [48]. However, it has been shown that these meta-analyses have produced biased accounts of the ...
AusPAR: Trastuzumab
... The drug substance is manufactured by Chinese Hamster Ovary (CHO) cells into which the DNA coding for the humanised immunoglobulin light and heavy chains has been inserted. The drug substance manufacture consists of cell culture fermentation and purification. The master cell bank and the working cel ...
... The drug substance is manufactured by Chinese Hamster Ovary (CHO) cells into which the DNA coding for the humanised immunoglobulin light and heavy chains has been inserted. The drug substance manufacture consists of cell culture fermentation and purification. The master cell bank and the working cel ...
Introduction to Anabolic Steroids
... Other proteins which can affect efficiency include RAF, which enhances the binding of the AR to DNA by about 25-fold; GRIP1, and cJun. None of these, unfortunately, could themselves be taken as drugs. But you can see that there are many ways by which AR activity could change besides any "upregulatio ...
... Other proteins which can affect efficiency include RAF, which enhances the binding of the AR to DNA by about 25-fold; GRIP1, and cJun. None of these, unfortunately, could themselves be taken as drugs. But you can see that there are many ways by which AR activity could change besides any "upregulatio ...
Product Monograph
... clinical trials for adjunctive treatment of epilepsy was 32% for 400 mg/day, and 1% for placebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mmol/L and >5 mmol/L decrease from pre-treatment ...
... clinical trials for adjunctive treatment of epilepsy was 32% for 400 mg/day, and 1% for placebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mmol/L and >5 mmol/L decrease from pre-treatment ...
SAFE n Smart* Use of Sulfonylureas
... A1. SUs are an effective, safe, well tolerated, affordable & convenient therapeutic option in the management of T2DM. A2. SUs are effective second line agents after metformin, in the management of T2DM. SU monotherapy as first line may be considered in Type 2 Diabetes with metformin intolerance/ con ...
... A1. SUs are an effective, safe, well tolerated, affordable & convenient therapeutic option in the management of T2DM. A2. SUs are effective second line agents after metformin, in the management of T2DM. SU monotherapy as first line may be considered in Type 2 Diabetes with metformin intolerance/ con ...
References - Specialist Pharmacy Service
... reported when agomelatine is taken with most other antidepressants so patients can be switched to and from this with negligible risk [3]. When switching from another antidepressant to agomelatine, agomelatine can be started whilst gradually withdrawing the first antidepressant. The exception is fluv ...
... reported when agomelatine is taken with most other antidepressants so patients can be switched to and from this with negligible risk [3]. When switching from another antidepressant to agomelatine, agomelatine can be started whilst gradually withdrawing the first antidepressant. The exception is fluv ...
Product Monograph Template - Standard - GlaxoSmithKline
... Although systemic effects have been minimal with recommended doses of FLONASE® aqueous nasal spray, potential risk increases with larger doses. Therefore, larger than recommended doses of FLONASE® aqueous nasal spray should be avoided. When intranasal steroids are used at higher than recommended dos ...
... Although systemic effects have been minimal with recommended doses of FLONASE® aqueous nasal spray, potential risk increases with larger doses. Therefore, larger than recommended doses of FLONASE® aqueous nasal spray should be avoided. When intranasal steroids are used at higher than recommended dos ...
What Is The “Safest” Non-Steroidal Anti
... (95% CI 1.21-1.54). A possible explanation for the disparate result is that diclofenac is the most selective for COX-2 compared with other conventional NSAIDs. This study also showed a slight cardioprotective effect of naproxen but without statistical significance (Table 2). Another meta-analysis wh ...
... (95% CI 1.21-1.54). A possible explanation for the disparate result is that diclofenac is the most selective for COX-2 compared with other conventional NSAIDs. This study also showed a slight cardioprotective effect of naproxen but without statistical significance (Table 2). Another meta-analysis wh ...
Guidance for Performing a Medication Error Potential Risk Assessment
... When the name of the medicine is a brand name, the generic name of the active ingredient should preferably be given prominence, but as a minimum standard be clear, easy to read and be in the same field of view as the critical information. There should be no intervening text ...
... When the name of the medicine is a brand name, the generic name of the active ingredient should preferably be given prominence, but as a minimum standard be clear, easy to read and be in the same field of view as the critical information. There should be no intervening text ...
Antifungal management in the haematology patient
... Open study of invasive aspergillosis with caspofungin as primary therapy 42 pts with allo HSCT , 24 eligible, Rx Caspofungin 70 then 50mg IV /d Unrelated donors in 16 patients; acute or chronic GVHD was present in 15, 12 patients were neutropenic (<500) at baseline, ...
... Open study of invasive aspergillosis with caspofungin as primary therapy 42 pts with allo HSCT , 24 eligible, Rx Caspofungin 70 then 50mg IV /d Unrelated donors in 16 patients; acute or chronic GVHD was present in 15, 12 patients were neutropenic (<500) at baseline, ...
An in vitro analysis of the output of salbutamol
... ODS1 column (4.6 mm ID; Fisher Chemicals, Loughborough, UK) was used with methanol±0.1% ammonium acetate as the mobile phase. The internal standard was benzyl biphenyl and ultraviolet detection was used at a wavelength of 276 nm. The limit of detection of the assay was <0.05 mg salbutamol.mL-1. The ...
... ODS1 column (4.6 mm ID; Fisher Chemicals, Loughborough, UK) was used with methanol±0.1% ammonium acetate as the mobile phase. The internal standard was benzyl biphenyl and ultraviolet detection was used at a wavelength of 276 nm. The limit of detection of the assay was <0.05 mg salbutamol.mL-1. The ...
GYNO-DAKTARIN™ Janssen Pharma
... be monitored. The effects and side effects of some other drugs (e.g., oral hypoglycemics and phenytoin), when co-administered with miconazole, can be increased and caution should be exercised. Contact should be avoided between latex products such as contraceptive diaphragms or condoms and GYNO-DAKTA ...
... be monitored. The effects and side effects of some other drugs (e.g., oral hypoglycemics and phenytoin), when co-administered with miconazole, can be increased and caution should be exercised. Contact should be avoided between latex products such as contraceptive diaphragms or condoms and GYNO-DAKTA ...
Long-term in vitro study of paclitaxel
... stent-induced intimal thickening of the lumen [22,23]. Paclitaxel's anti-proliferative effect is reversible [24]. Its short cellular residence time (1 h), along with the reversible anti-proliferative activity, suggest that it should be formulated in sustainedrelease dosage form [25]. The TAXUS trial ...
... stent-induced intimal thickening of the lumen [22,23]. Paclitaxel's anti-proliferative effect is reversible [24]. Its short cellular residence time (1 h), along with the reversible anti-proliferative activity, suggest that it should be formulated in sustainedrelease dosage form [25]. The TAXUS trial ...
Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword
... sergliflozin and rest of three subjects in each cohort were on placebo. The treatment was given three times per day for 14 days. Sergliflozin was well tolerated in both cohorts and had stable pharmacokinetic parameters. After 14 days treatment, subjects treated with sergliflozin reduced bodyweight o ...
... sergliflozin and rest of three subjects in each cohort were on placebo. The treatment was given three times per day for 14 days. Sergliflozin was well tolerated in both cohorts and had stable pharmacokinetic parameters. After 14 days treatment, subjects treated with sergliflozin reduced bodyweight o ...
EXFORGE 5/80 EXFORGE 5/160 EXFORGE 10/160
... Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with cough. In clinical trials where valsartan ...
... Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with cough. In clinical trials where valsartan ...
Relationship between the Serotonergic Activity and Reinforcing
... Vanover et al., 1992; Howell and Byrd, 1995). Among amphetamine-like drugs that are not as selective for 5-HT activity, Ritz and Kuhar (1989) reported a negative correlation between potency as a reinforcer and binding affinity at the 5-HT transporter (SERT). The depletion of 5-HT by medial forebrain ...
... Vanover et al., 1992; Howell and Byrd, 1995). Among amphetamine-like drugs that are not as selective for 5-HT activity, Ritz and Kuhar (1989) reported a negative correlation between potency as a reinforcer and binding affinity at the 5-HT transporter (SERT). The depletion of 5-HT by medial forebrain ...
CIPROXIN Tablets PI
... Drugs which delay peristalsis, e.g., opiates and diphenoxylate with atropine (Lomotil), may prolong and/or worsen the condition and should not be used. Effects on the Liver Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin. In the event of any sign ...
... Drugs which delay peristalsis, e.g., opiates and diphenoxylate with atropine (Lomotil), may prolong and/or worsen the condition and should not be used. Effects on the Liver Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin. In the event of any sign ...
[Product Monograph Template
... discontinuation of NATESTO. Check hematocrit prior to initiating testosterone treatment. It would be appropriate to re-evaluate the hematocrit 3 to 6 months after starting testosterone treatment, and then annually. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an accepta ...
... discontinuation of NATESTO. Check hematocrit prior to initiating testosterone treatment. It would be appropriate to re-evaluate the hematocrit 3 to 6 months after starting testosterone treatment, and then annually. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an accepta ...
Blood Drugs
... vessels has an anticoagulant phenotype, and circulating blood platelets and clotting factors do not normally adhere to it to an appreciable extent Following disruption of the endothelial lining and exposure of blood to the subendothelial vessel wall, platelets adhere to and virtually cover the expos ...
... vessels has an anticoagulant phenotype, and circulating blood platelets and clotting factors do not normally adhere to it to an appreciable extent Following disruption of the endothelial lining and exposure of blood to the subendothelial vessel wall, platelets adhere to and virtually cover the expos ...
the 2014 drug trend report
... result of merger and acquisition activity among pharmaceutical manufacturers and drug distributors. Fewer manufacturers means less competition and increased prices. There now is only one – or at most, two – generic manufacturers of some specific products, for example, digoxin, when there used to be ...
... result of merger and acquisition activity among pharmaceutical manufacturers and drug distributors. Fewer manufacturers means less competition and increased prices. There now is only one – or at most, two – generic manufacturers of some specific products, for example, digoxin, when there used to be ...
Simulation Based Assessment of Limited Sampling Strategies
... of the LSS, their predictive power and transferability should not be taken for granted when different patient subpopulations and contexts are involved [18]. This fact explains the variety of LSS reported for the same drug by different research groups [9,19]. When a specific LSS is intended to be use ...
... of the LSS, their predictive power and transferability should not be taken for granted when different patient subpopulations and contexts are involved [18]. This fact explains the variety of LSS reported for the same drug by different research groups [9,19]. When a specific LSS is intended to be use ...
Sandostatin, Sandostatin Lar Depot (Octreotide Acetate)
... to a decelerating effect on lymph flow, although their exact mechanism of action is not well defined. In successful cases, a substantial reduction of lymph drainage through the chest tube is evident within the first few days of commencing the drug, and treatment lasts for 1-2 weeks. Treatment failur ...
... to a decelerating effect on lymph flow, although their exact mechanism of action is not well defined. In successful cases, a substantial reduction of lymph drainage through the chest tube is evident within the first few days of commencing the drug, and treatment lasts for 1-2 weeks. Treatment failur ...
Reactions to ASA/NSAIDS/and Additives
... • Single blind placebo controlled: N = 2 • Double blind placebo controlled: N = 0 ...
... • Single blind placebo controlled: N = 2 • Double blind placebo controlled: N = 0 ...
a guide to use of common palliative care drugs in renal impairment
... • Cockcroft-Gault formula is used in drug manufacturer’s information so drug dosing is based on renal function derived using this formula. For the majority of patients, the difference in GFR using either equation will not lead to a difference in drug dosages, except in patients whose body size is ve ...
... • Cockcroft-Gault formula is used in drug manufacturer’s information so drug dosing is based on renal function derived using this formula. For the majority of patients, the difference in GFR using either equation will not lead to a difference in drug dosages, except in patients whose body size is ve ...
Committee on Drugs 1998;101;1079 Pediatrics
... hypertensive episodes, severe mood swings, cerebrovascular accidents, myocardial infarction, and repeated spontaneous abortions.45,46,49 –53 Infant characteristics that may be associated with maternal drug use include prematurity;11,52 unexplained intrauterine growth retardation;50,52 neurobehaviora ...
... hypertensive episodes, severe mood swings, cerebrovascular accidents, myocardial infarction, and repeated spontaneous abortions.45,46,49 –53 Infant characteristics that may be associated with maternal drug use include prematurity;11,52 unexplained intrauterine growth retardation;50,52 neurobehaviora ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.